2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in …

SM Goodman, B Springer, G Guyatt… - Arthritis & …, 2017 - Wiley Online Library
Objective This collaboration between the American College of Rheumatology and the
American Association of Hip and Knee Surgeons developed an evidence‐based guideline …

Adverse effects of biologics: a network meta‐analysis and Cochrane overview

JA Singh, GA Wells, R Christensen… - Cochrane database …, 2011 - cochranelibrary.com
Background Biologics are used for the treatment of rheumatoid arthritis and many other
conditions. While the efficacy of biologics has been established, there is uncertainty …

Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident …

H Choi, RH Lee, N Bazhanov, JY Oh… - Blood, The Journal of …, 2011 - ashpublications.org
Human mesenchymal stem/progenitor cells (hMSCs) repair tissues and modulate immune
systems but the mechanisms are not fully understood. We demonstrated that hMSCs are …

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

MA Lopez-Olivo, JH Tayar, JA Martinez-Lopez… - Jama, 2012 - jamanetwork.com
Context Concerns exist regarding the potential development of malignancies in patients with
rheumatoid arthritis (RA) who are receiving biologic response modifiers (BRMs). Objective …

Extra-articular manifestations of rheumatoid arthritis: an update

M Prete, V Racanelli, L Digiglio, A Vacca… - Autoimmunity …, 2011 - Elsevier
Rheumatoid arthritis (RA) is an immune-mediated disease involving chronic low-grade
inflammation that may progressively lead to joint destruction, deformity, disability and even …

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

KJ Aaltonen, LM Virkki, A Malmivaara, YT Konttinen… - PloS one, 2012 - journals.plos.org
Background and Objectives Five-tumour necrosis factor (TNF)-blockers (infliximab,
etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of …

A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis

M Hayder, M Poupot, M Baron, D Nigon… - Science translational …, 2011 - science.org
Dendrimers are highly branched “tree-like” polymers that have demonstrated therapeutic
potential in drug delivery, medical imaging, and tissue engineering in recent years. In …

Malignancy risk and recurrence with psoriasis and its treatments: a concise update

S Geller, H Xu, M Lebwohl, B Nardone… - American journal of …, 2018 - Springer
Psoriasis is a common inflammatory cutaneous disease that affects approximately 120
million people worldwide. Systemic treatments have significantly improved disease burden …

Paradoxical inflammation induced by anti-TNF agents in patients with IBD

I Cleynen, S Vermeire - Nature reviews Gastroenterology & hepatology, 2012 - nature.com
Anti-TNF antibodies have acquired a prominent place in the management of IBD (including
Crohn's disease and ulcerative colitis), rheumatologic conditions (such as rheumatoid …

Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view

S Hu, S Liang, H Guo, D Zhang, H Li, X Wang… - Journal of Biological …, 2013 - ASBMB
TNFα-targeting therapy with the use of the drugs Etanercept, Infliximab, and Adalimumab is
used in the clinical treatment of various inflammatory and immune diseases. Although all of …